Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics (PRQR) Income from Non-Controlling Interests (2021 - 2023)

Historic Income from Non-Controlling Interests for ProQR Therapeutics (PRQR) over the last 3 years, with Q3 2023 value amounting to $315691.2.

  • ProQR Therapeutics' Income from Non-Controlling Interests rose 213643.22% to $315691.2 in Q3 2023 from the same period last year, while for Dec 2023 it was $416834.7, marking a year-over-year increase of 7841.84%. This contributed to the annual value of $415379.6 for FY2023, which is 8506.19% up from last year.
  • As of Q3 2023, ProQR Therapeutics' Income from Non-Controlling Interests stood at $315691.2, which was up 213643.22% from $17422.8 recorded in Q2 2023.
  • In the past 5 years, ProQR Therapeutics' Income from Non-Controlling Interests ranged from a high of $315691.2 in Q3 2023 and a low of -$25944.3 during Q3 2021
  • Its 3-year average for Income from Non-Controlling Interests is $52825.8, with a median of -$3060.7 in 2022.
  • In the last 5 years, ProQR Therapeutics' Income from Non-Controlling Interests skyrocketed by 284678.55% in 2022 and then crashed by 9247.56% in 2023.
  • Over the past 3 years, ProQR Therapeutics' Income from Non-Controlling Interests (Quarter) stood at -$21735.5 in 2021, then skyrocketed by 85.92% to -$3060.7 in 2022, then soared by 10414.21% to $315691.2 in 2023.
  • Its Income from Non-Controlling Interests stands at $315691.2 for Q3 2023, versus $17422.8 for Q2 2023 and $83720.7 for Q1 2023.